权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Adaptation of Mia® (Mammography Intelligence Assessment) to support breast screening programmes to address Covid-19-related breast screening backlog

采用 Mia®（乳房 X 线摄影情报评估）来支持乳房筛查计划，以解决与 Covid-19 相关的乳房筛查积压问题

基本信息

批准号：
56897
负责人：
金额：
$ 9.53万
依托单位：
KHEIRON MEDICAL TECHNOLOGIES LTD
依托单位国家：
英国
项目类别：
Feasibility Studies
财政年份：
2020
资助国家：
英国
起止时间：
2020 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=56897
关键词：
Adaptation Mia Mammography Intelligence Assessment

项目摘要

Due to the Covid-19 outbreak, multiple routine NHS services are on pause, including breast screening programmes. An estimated 3-9 month delay in women being screened will lead to more cancers being missed at the stage where they are easier to treat and immense pressure on an already overburdened system. Our breast cancer screening AI solution Mia (Mammography intelligent assessment) can help solve this impending crisis by automating some aspects of the breast screening programme whilst maintaining current screening performance standards. We have developed a phased approach aligned with the way the human breast radiology readers are brought into the breast screening service and this requires a thorough validation. With breast radiologists, we will validate and test Mia in the pre-commercial period and build trust in the AI. With our NHS partners, we will develop the prospective clinical evidence required for the accelerated adoption of Mia in time to tackle the impending crisis. The output of the project will be an AI solution that can be fast-tracked to reduce the backlogs caused by Covid-19 and give every woman in the UK a better fighting chance against breast cancer.

由于新冠肺炎疫情爆发，多项常规NHS服务暂停，包括乳房筛查项目。据估计，妇女接受筛查的3-9个月延迟将导致更多的癌症在更容易治疗的阶段被遗漏，并给已经负担过重的系统带来巨大压力。我们的乳腺癌筛查AI解决方案Mia（乳腺X线摄影智能评估）可以通过自动化乳腺筛查计划的某些方面，同时保持当前的筛查性能标准，帮助解决这一迫在眉睫的危机。我们已经开发了一种分阶段的方法，与人类乳腺放射学读者进入乳腺筛查服务的方式相一致，这需要彻底的验证。与乳腺放射科医生一起，我们将在商业化前验证和测试Mia，并建立对AI的信任。与我们的NHS合作伙伴一起，我们将及时开发加速采用MIA所需的前瞻性临床证据，以应对即将到来的危机。该项目的成果将是一个人工智能解决方案，可以快速跟踪，以减少由Covid-19造成的积压，并为英国的每个女性提供更好的抗击乳腺癌的机会。